Nurix Therapeutics ( NASDAQ: NRIX ) on Tuesday filed an automatic shelf registration statement on Form S-3 related to a mixed securities offering. Pursuant to the registration statement , the biopharmaceutical company may offer common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, subscription rights to purchase common stock, preferred stock or debt securities, and/or units consisting of some or all of these securities in any combination. Net proceeds from the sale may be used for general corporate purposes.
More on Nurix Therapeutics Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies Biggest stock movers today: JPM, APLD, and more Nurix Therapeutics prices upsized stock offering to raise $175 million Seeking Alpha’s Quant Rating on Nurix Therapeutics Historical earnings data for Nurix Therapeutics.
